To include your compound in the COVID-19 Resource Center, submit it here.

Ultragenyx reports interim Phase I/II data for DTX301 in OTC deficiency

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported interim data from three evaluable patients in the first cohort of a Phase I/II trial evaluating a single peripheral IV infusion of 2x1012 GC/kg DTX301 to

Read the full 312 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE